drugset / Trial / NCT02762123

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

NCT02762123

Phase 1 Completed 28 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The study is being conducted to assess the effect of BMS-986142 on the single-dose PK parameters of montelukast, flurbiprofen, omeprazole, midazolam, and digoxin, probe drugs for (cytochome P450) CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein (P-gp), respectively.

Timeline

Start
2016-05
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986142 Small molecule 200 mg Oral
Subject BMS-986142 Small molecule 350 mg Oral
Subject Digoxin Other / unclassified
Subject Flurbiprofen Small molecule
Subject Midazolam Small molecule
Subject Montelukast Other / unclassified
Subject Omeprazole Other / unclassified

Indications